Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

205 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer.
Zilenaite-Petrulaitiene D, Rasmusson A, Besusparis J, Valkiuniene RB, Augulis R, Laurinaviciene A, Plancoulaine B, Petkevicius L, Laurinavicius A. Zilenaite-Petrulaitiene D, et al. Among authors: rasmusson a. Virchows Arch. 2024 Jan 13. doi: 10.1007/s00428-024-03737-4. Online ahead of print. Virchows Arch. 2024. PMID: 38217716
Bimodality of intratumor Ki67 expression is an independent prognostic factor of overall survival in patients with invasive breast carcinoma.
Laurinavicius A, Plancoulaine B, Rasmusson A, Besusparis J, Augulis R, Meskauskas R, Herlin P, Laurinaviciene A, Abdelhadi Muftah AA, Miligy I, Aleskandarany M, Rakha EA, Green AR, Ellis IO. Laurinavicius A, et al. Among authors: rasmusson a. Virchows Arch. 2016 Apr;468(4):493-502. doi: 10.1007/s00428-016-1907-z. Epub 2016 Jan 27. Virchows Arch. 2016. PMID: 26818835 Free article.
Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma.
Zilenaite D, Rasmusson A, Augulis R, Besusparis J, Laurinaviciene A, Plancoulaine B, Ostapenko V, Laurinavicius A. Zilenaite D, et al. Among authors: rasmusson a. Front Oncol. 2020 Jun 16;10:950. doi: 10.3389/fonc.2020.00950. eCollection 2020. Front Oncol. 2020. PMID: 32612954 Free PMC article.
Intratumoral Heterogeneity and Immune Response Indicators to Predict Overall Survival in a Retrospective Study of HER2-Borderline (IHC 2+) Breast Cancer Patients.
Radziuviene G, Rasmusson A, Augulis R, Grineviciute RB, Zilenaite D, Laurinaviciene A, Ostapenko V, Laurinavicius A. Radziuviene G, et al. Among authors: rasmusson a. Front Oncol. 2021 Nov 11;11:774088. doi: 10.3389/fonc.2021.774088. eCollection 2021. Front Oncol. 2021. PMID: 34858854 Free PMC article.
205 results